

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
GlaxoSmithKline, LLC.	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Janssen Global Services, LLC	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Janssen Global Services, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Kentucky Bioprocessing, Inc	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i>
MedImmune, LLC	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical trials <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Medscape	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical trials research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Micron Technology	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical Trials research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
PaxVax	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical trials research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
PFIZER CANADA INC	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
PFIZER CANADA INC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Regeneron Pharmaceuticals, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical trials research <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

SANOPI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> Emory University <i>Grant / Contract Description:</i> Clinical trial-related work <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
SANOPI PASTEUR INC.	End Point Review Committee	Self
<i>Category:</i> End Point Review Committee <i>Additional Information:</i>		<i>Description:</i>
SANOPI PASTEUR INC.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i>
SANOPI PASTEUR INC.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Vice President, Clinical Development <i>Additional Information:</i>		<i>Position Description:</i>
Moderna	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bill and Melinda Gates Foundation	Grant / Contract	Self
<i>Recipient Name:</i> Lindsey Baden <i>Grant / Contract Description:</i> Vaccine and mAb development for Infectious Diseases <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Harvard Medical School	Grant / Contract	Self
<i>Recipient Name:</i> Lindsey Baden <i>Grant / Contract Description:</i> Support clinical research, Covid response <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Lindsey Baden <i>Grant / Contract Description:</i> NIAID, NCATS. Support multiple activities: vaccine development, CTSA <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Wellcome Trust	Grant / Contract	Self
<i>Recipient Name:</i> Lindsey Baden <i>Grant / Contract Description:</i> Develop Cholera Vaccine <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

- a. **Please describe those relationships.**

Dr. Baden reports grants from NIH/NIAID for the conduct of this study; in addition grants from NIH/ NIAID, Gates Foundation, and Wellcome Trust, outside the submitted work; and Dr. Baden is a Deputy Editor at the New England Journal of Medicine. Dr. Baden is involved in HIV, other pathogens, and COVID vaccine clinical trials conducted in collaboration with the NIH, HIV Vaccine Trials Network (HVTN), COVID Vaccine Prevention Network (CoVPN), International AIDS Vaccine Initiative (IAVI), Crucell/ Janssen, Moderna, Military HIV Research Program (MHRP), Gates Foundation, and the Ragon Institute.

2. **What is the manuscript title?**

Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Hana M. El Sahly, M.D.,1* Lindsey R. Baden, M.D.,2* Brandon Essink, M.D.,3 Susanne Doblecki-Lewis, M.D.,4 Judith M. Martin, M.D.,5 Evan J. Anderson, M.D.,6 Thomas B. Campbell, M.D.,7 Jesse Clark, M.D.,8 Lisa A. Jackson, M.D.,9 Carl J. Fichtenbaum, M.D.,10 Marcus Zervos, M.D.,11 Bruce Rankin, D.O.,12 Frank Eder, M.D.,3 Gregory Feldman, M.D.,13 Christina Kennelly, M.D.,14 Laurie Han-Conrad, M.D.,15 Michael Levin, M.D.,16 Kathleen M. Neuzil, M.D.,17 Lawrence Corey, M.D.,18 Peter Gilbert, Ph.D.,18 Holly Janes, Ph.D.,18 Dean Follmann, Ph.D.,19 Mary Marovich, M.D.,19 Laura Polakowski, M.D.,19 John R. Mascola, M.D.,20 Julie E. Ledgerwood, D.O.,20 Barney S. Graham, M.D.,20 Allison August, M.D.,21 Heather Clouting, MSc.,21 Weiping Deng, Ph.D.,21 Shu Han, PhD,21 Brett Leav, M.D.,21 Deb Manzo, MSc.,21 Rolando Pajon, Ph.D.,21 Florian Schödel, M.D.,PhD,21 Joanne E. Tomassini, Ph.D.,21 Honghong Zhou, Ph.D.,21 Jacqueline Miller, M.D.,21 on behalf of the COVE Study Group

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Moderna, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Clinical Operations Lead

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Lawrence Corey <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Director, Biostatistics		<i>Position Description:</i> Provide statistical support for clinical trial designs and protocol development, author statistical analysis plans, oversee dataset derivations, statistical analyses and reporting, ensure data quality in the clinical study reports and manuscripts.
<i>Additional Information:</i> Full time employee. Restricted stock units and stock options granted.		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Re: Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Other - Grant to the Institution

Recipient Name: Baylor college of Medicine
Grant / Contract Description: VTEU Grant- UM1 AI48575-02S2
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
Yes.
 - Please describe those relationships.**
Dr. El Sahly reports grants from The National Institutes of Health, during the conduct of the study, 3UM1AI148575-01S2
- What is the manuscript title?**
Phase 3 trial of mRNA-1273 SARS-CoV-2 vaccine: completion of blinded phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
GlaxoSmithKline	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 10 hr		<i>Description:</i> Pharmaceutical talks
Mylan Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 12 hours		<i>Description:</i> Pharmaceutical consulting board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Amgen Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Carl Fichtenbaum <i>Grant / Contract Description:</i> Research study on lipid-lowering agent in HIV <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Gilead Sciences Inc	Grant / Contract	Self
<i>Recipient Name:</i> Carl Fichtenbaum <i>Grant / Contract Description:</i> Multiple research studies <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Merck	Grant / Contract	Self
<i>Recipient Name:</i> Carl Fichtenbaum <i>Grant / Contract Description:</i> Research studies in HIV <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
ViiV Healthcare Company	Grant / Contract	Self
<i>Recipient Name:</i> Carl Fichtenbaum <i>Grant / Contract Description:</i> Multiple research studies in HIV <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Intellectual Property

Type	Is Licensed	Interest Held By												
Patent - Prefusion coronavirus spike proteins and their u	No	Self												
<i>Description:</i> Prefusion coronavirus spike proteins and their use <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> EU <i>Licensees:</i>		<i>Patent Number:</i> Europe Patent Application No. 17800655.7 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i>												
Patent - Prefusion coronavirus spike proteins and their u	Yes	Self												
<i>Description:</i> Prefusion coronavirus spike proteins and their use <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> USA <i>Licensees:</i> <table border="1" data-bbox="45 766 792 913"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>Medigen Vaccine Biologics Corp.</td> <td>Prefusion coronavirus spike proteins and their use</td> <td>9/1/20</td> </tr> <tr> <td>SANOFI PASTEUR INC.</td> <td>Prefusion coronavirus spike proteins and their use</td> <td>9/1/20</td> </tr> <tr> <td>BioNTech AG</td> <td>Prefusion coronavirus spike proteins and their use</td> <td>9/1/20</td> </tr> </tbody> </table>		Licensee	Title	Date	Medigen Vaccine Biologics Corp.	Prefusion coronavirus spike proteins and their use	9/1/20	SANOFI PASTEUR INC.	Prefusion coronavirus spike proteins and their use	9/1/20	BioNTech AG	Prefusion coronavirus spike proteins and their use	9/1/20	<i>Patent Number:</i> US Patent No. 10,960,070 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> This is a U.S. government patent on which I am the first named inventor. I will receive capped royalties according to NIH policy. All licenses are non-exclusive, and I have listed 3 licensees but there are others under confidentiality
Licensee	Title	Date												
Medigen Vaccine Biologics Corp.	Prefusion coronavirus spike proteins and their use	9/1/20												
SANOFI PASTEUR INC.	Prefusion coronavirus spike proteins and their use	9/1/20												
BioNTech AG	Prefusion coronavirus spike proteins and their use	9/1/20												
Patent - SARS-CoV-2 Vaccine	No	Self												
<i>Description:</i> SARS-CoV-2 Vaccine <i>Patent Status:</i> Provisional <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> PCT Patent Application No. PCT/US2021/017709 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i>												

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617 variants
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> Kaiser Permanente Washington		<i>Recipient Type:</i> Institution
<i>Grant / Contract Description:</i> Funding for the conduct of a Phase 3 vaccine trial		<i>Grant / Contract Purpose:</i> Research
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Received payment for PI of Moderna COVE study

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Vice President, COVID-19 Program Lead <i>Additional Information:</i> Salaried employee with stock holdings in company.		<i>Position Description:</i> Responsible for clinical development program for the SARS-CoV-2 vaccine.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna Therapeutics, Inc	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Merck	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> consultant on an unrelated project

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Therapeutic Area Head, Infectious Diseases		<i>Position Description:</i> Head of development activities for vaccines and monoclonal antibodies at Moderna
<i>Additional Information:</i>		
Moderna	Stock	Self
<i>Additional Information:</i>		
Moderna	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety, Immunogenicity and Efficacy of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents 12 to <18 Years of Age
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> Kathleen Neuzil <i>Grant / Contract Description:</i> Phase I Clinical trial of mRNA vaccine candidate <i>Additional Information:</i> Dr. Neuzil received no salary support. Her institution received support for conduct of this trial.		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Director Clinical Biomarkers <i>Additional Information:</i>		<i>Position Description:</i>
Moderna	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Moderna	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> member of scientific advisory board and advisor

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-13017

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
mrna vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-13017

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Sr. Director <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics
Moderna	Stock	Self
<i>Additional Information:</i> As an employee of Moderna, i am also a stock holder of Moderna stock		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Phase 3 Trial of mRNA-1273 SARS-CoV-2 Vaccine: Completion of Blinded Phase
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.